Abstract
A 62-year-old man had chronic hepatitis B virus (HBV) infection and was diagnosed with liver cirrhosis. At the time of diagnosis the patient’s virologic markers were positive for hepatitis B surface antigen (HBsAg), antibody to hepatitis B e antigen (anti-HBe) and antibody to hepatitis B core antigen (anti-HBc), while antibody to hepatitis B surface antigen (anti-HBs) and HBV DNA were negative. Later the patient received chemotherapy for malignancy. However, this was interrupted due to elevated liver enzymes. At the same time HBV DNA became positive. Lamivudine (LMV) therapy was administered immediately. However, the levels of serum aminotransferase and total bilirubin (TB) were still rising. Finally the patient died of fulminant hepatic failure. A sequence revealed HBV genotype C (HBsAg subtype adw) with immune escape mutations, F8L, S34L, F41S, G44V, F93C, V96G, L110I, C149Y and F161Y. The high morbidity and mortality of this complication is one of the major obstacles to completing the standard treatment for malignancy in HBV carriers. Therefore, the relative risk of antiviral prophylactic failure should be further assessed and the optimal strategy for antiviral prophylaxis in HBsAg-positive patients with oncologic and hematologic malignancies undergoing chemotherapy should be revised.
References
Dienstag J L, Schiff E R, Wright T L, et al. 1999. Lamivudine as initial treatment for chronic hepatitis b in the united states. N Engl J Med, 341(17): 1256–1263.
Ferreira R, Carvalheiro J, Torres J, et al. 2012. Fatal hepatitis b reactivation treated with entecavir in an isolated anti-hbs positive lymphoma patient: A case report and literature review. Saudi J Gastroenterol, 18(4): 277–281.
Fukushima N, Mizuta T, Tanaka M, et al. 2009. Retrospective and prospective studies of hepatitis b virus reactivation in malignant lymphoma with occult hbv carrier. Ann Oncol, 20(12): 2013–2017.
Kim I K, Kim B G, Kim W, et al. 2012. Clinical prediction of failure of lamivudine prophylaxis for patients with hepatitis b infection undergoing cytotoxic chemotherapy for malignancy. Antimicrob Agents Chemother. 56(11): 5511–5519.
Kondili L A, Osman H, Mutimer D. 2004. The use of lamivudine for patients with acute hepatitis b (a series of cases). J Viral Hepat, 11(5): 427–431.
Lai C L, Chien R N, Leung N W, et al. 1998. A one-year trial of lamivudine for chronic hepatitis b. Asia hepatitis lamivudine study group. N Engl J Med, 339(2): 61–68.
Lee I C, Huang Y H, Chu C J, et al. 2010. Hepatitis b virus reactivation after 23 months of rituximab-based chemotherapy in an hbsag-negative, anti-hbs-positive patient with follicular lymphoma. J Chin Med Assoc, 73(3): 156–160.
Lu M, Lorentz T. 2003. De novo infection in a renal transplant recipient caused by novel mutants of hepatitis b virus despite the presence of protective anti-hepatitis b surface antibody. J Infect Dis, 187(8): 1323–1326.
Matsue K, Kimura S, Takanashi Y, et al. 2010. Reactivation of hepatitis b virus after rituximab-containing treatment in patients with cd20-positive b-cell lymphoma. Cancer, 116(20): 4769–4776.
Miyake Y, Iwasaki Y, Takaki A, et al. 2008. Lamivudine treatment improves the prognosis of fulminant hepatitis b. Intern Med, 47(14): 1293–1299.
Norder H, Couroucé A M, Coursaget P, et al. 2004. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology, 47(6):289–309.
Schmilovitz-Weiss H, Ben-Ari Z, Sikuler E, et al. 2004. Lamivudine treatment for acute severe hepatitis b: A pilot study. Liver Int, 24(6): 547–551.
Tillmann H L, Hadem J, Leifeld L, et al. 2006. Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis b, a multicenter experience. J Viral Hepat, 13(4): 256–263.
Yeo W, Chan T C, Leung N W, et al. 2009. Hepatitis b virus reactivation in lymphoma patients with prior resolved hepatitis b undergoing anticancer therapy with or without rituximab. J Clin Oncol, 27(4): 605–611.
Yuen M F, Sablon E, Hui C K, et al. 2001. Factors associated with hepatitis b virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology, 34(4 Pt 1): 785–791.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Foundation items: National Basic Research Priorities Program of China (2011CB 106303); The National Natural Science Foundation of China (31200699); The Fundamental Research Funds for the Central Universities (HUST: 2012QN140).
Rights and permissions
About this article
Cite this article
Wu, C., Shi, H., Wang, Y. et al. A case of hepatitis B reactivation due to the hepatitis B virus escape mutant in a patient undergoing chemotherapy. Virol. Sin. 27, 368–371 (2012). https://doi.org/10.1007/s12250-012-3284-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12250-012-3284-3